Novo Nordisk made an unsolicited bid to acquire Metsera for $6.5 billion upfront and $2.5 billion in contingent value rights. Metsera deemed Novo’s offer “superior” to Pfizer’s $4.9 billion cash offer. Novo may need Metsera’s pipeline due to market share loss. Pfizer could also make a competing bid.

Pfizer’s obesity pipeline was weakened by discontinuation of two oral GLP-1s. Novo’s offer doesn’t change fair value estimate. Regulatory and legal risks may arise from Novo/Metsera combination. Metsera’s pipeline may offer differentiating qualities. Pfizer has four days to respond to Novo’s offer.

Novo must sway Metsera’s board and overcome regulatory challenges. Pfizer may fight for Metsera. Offer doesn’t change Novo’s fair value estimate. Metsera’s pipeline may lead to commercial success. Novo and Pfizer could face anticompetitive concerns. Morningstar’s analysis was originally published as a stock note.

Read more at Morningstar: Novo Nordisk: Confirmed as Other Leading Metsera Bidder, Now Publicly Fighting for Deal